Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/193597
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saponaro, Mariarosaria | - |
dc.contributor.author | Annunziata, Luigi | - |
dc.contributor.author | Turla, Antonella | - |
dc.contributor.author | Viganò, Ilaria | - |
dc.contributor.author | Laurentiis, Michele De | - |
dc.contributor.author | Giuliano, Mario | - |
dc.contributor.author | Mastro, Lucia del | - |
dc.contributor.author | Montemurro, Filippo | - |
dc.contributor.author | Puglisi, Fabio | - |
dc.contributor.author | Angelis, Carmine De | - |
dc.contributor.author | Buono, Giuseppe | - |
dc.contributor.author | Schettini, Francesco | - |
dc.contributor.author | Arpino, Grazia | - |
dc.date.accessioned | 2023-02-14T14:13:19Z | - |
dc.date.available | 2023-02-14T14:13:19Z | - |
dc.date.issued | 2022-11-06 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | http://hdl.handle.net/2445/193597 | - |
dc.description.abstract | In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ijms232113604 | - |
dc.relation.ispartof | International Journal of Molecular Sciences, 2022, vol. 23, num. 21, p. 13604 | - |
dc.relation.uri | https://doi.org/10.3390/ijms232113604 | - |
dc.rights | cc-by (c) Saponaro, Mariarosaria et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Tractament adjuvant del càncer | - |
dc.subject.classification | Hormonoteràpia | - |
dc.subject.classification | Receptors d'hormones | - |
dc.subject.classification | Genòmica | - |
dc.subject.classification | Efectes secundaris | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Adjuvant treatment of cancer | - |
dc.subject.other | Hormone therapy | - |
dc.subject.other | Hormone receptors | - |
dc.subject.other | Genomics | - |
dc.subject.other | Side effects | - |
dc.title | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 729774 | - |
dc.date.updated | 2023-02-14T14:13:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36362392 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
729774.pdf | 314.22 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License